

## Prolensa<sup>®</sup> (bromfenac) – First-time generic

- On January 9, 2024, [Lupin launched](#) an [AB-rated](#) generic version of Bausch Health's [Prolensa \(bromfenac\)](#) ophthalmic 0.07% solution.
  - Lupin was granted 180-days of generic exclusivity.
- Prolensa is approved for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
- Bromfenac is also available generically as an [ophthalmic 0.09% solution](#) and brand ophthalmic 0.075% solution ([Bromsite<sup>®</sup>](#)) carrying the same indication as Prolensa.
- According to IQVIA data, Prolensa had annual sales of \$182 million as of November 2023.